Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

LifeCannMD

JULY 3, 2024

Various clinical trials are investigating the effectiveness of cannabis and its components in treating PTSD symptoms. While preliminary research and anecdotal evidence are promising, more rigorous clinical trials are needed to establish standardized treatment protocols and ensure safety.

Treatment 96

Treatment Clinical Trials Marijuana Sleep 96

Veriheal

JANUARY 11, 2023

Not only this, but Gaize recently completed the largest clinical trial into cannabis impairment , and the results are set to transform the realm of workplace and road safety. How do you feel about this being the largest cannabis impairment clinical trial ever? Here’s what he had to say.

Clinical Trials 98

Clinical Trials THC Data Safety 98

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. ” Simply put, there is the expectation that ongoing and future clinical trials will further establish therapeutic potential in using psilocybin for OCD.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

MMJ Recs

JULY 30, 2024

Advocates call for expanded research initiatives, including large-scale clinical trials with standardized protocols and investigations into specific cannabinoid formulations and delivery methods. While early research is promising, more rigorous studies are needed to establish efficacy, safety, and optimal dosing strategies.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 8, 2021

For more information, please visit [link]. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. All statements other than statements of historical fact may be forward-looking statements or information.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

JUNE 21, 2021

RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. But if that doctor has access to information from 40,000 patients it’s a different story.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

JULY 9, 2024

Read our post Understanding the Endocannabinoid System: A Guide for Medical Marijuana Patients for more detailed information. Some clinical trials have shown that cannabinoids, particularly THC and CBD, effectively reduce muscle spasticity and pain in MS patients.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

MMJ Recs

JULY 3, 2024

From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. For more information, read our post “ Understanding the Endocannabinoid System: A Guide for Medical Marijuana Patients ”.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JANUARY 12, 2022

This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Danielle Schlosser PhD appointed Senior Vice-President, Clinical Innovation, to lead therapist research and training, bringing her clinical experience in behavioural health and expertise in digital health innovation. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 28, 2021

More information about the organization is available at [link]. Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. MAPS PBC is committed to the evolution of psychedelic healing modalities.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

MARCH 1, 2022

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Knowledge of Canadian, Australian and New Zealand clinical trial regulations and procedures is a plus.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. CBD Dosage Guidelines for Medical Use Determining the appropriate dosage of CBD for medical use is crucial to ensure optimal efficacy and safety.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

The Cannigma

FEBRUARY 2, 2021

We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”. million clinical trial investigating the effects of CBD on hallucinations and delusions related to the disease. Still, research is ongoing.

Patients 89

Patients Clinical Trials Research and Development Treatment 89

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. This is largely due to the way THC interacts and binds with endocannabinoids in our ECS.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

MMJ Recs

JULY 5, 2024

Numerous clinical trials are underway to further investigate THC’s efficacy, safety, and potential interactions with other medications as well. These trials aim to provide more conclusive evidence for its use in mainstream medicine. While promising, its use entails risks that necessitate careful consideration.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

JUNE 17, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. More information can be found at www.dsm.com/venturing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. For more information, visit www.mymd.com. Eurofins is testing for life.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

OCTOBER 2, 2021

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Knowledge of Canadian, Australian and New Zealand clinical trial regulations and procedures is a plus.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. It covers the pipeline drug profiles, including clinical and nonclinical stage products. For more information about this clinical trials report visit [link].

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

JULY 28, 2021

Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. ” Next Steps. ” Next Steps. dcohen@pharmadrug.co.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

MMJ Recs

MAY 9, 2024

It’s essential for veterans using medical marijuana to stay informed about the legal landscape and seek guidance from legal professionals familiar with cannabis laws in their state. State Veterans Affairs Offices: Many state veterans affairs offices provide information and support services related to medical marijuana.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

MMJ Recs

JULY 19, 2024

By understanding the mechanisms and nuances of cannabis use, individuals can make informed decisions about integrating it into their treatment regimen. Clinical Research Findings: What Studies Say About Cannabis and Anxiety Numerous studies have explored cannabis’s efficacy in alleviating anxiety symptoms.

Strains 52

Strains Indica Clinical Trials Terpenes 52

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8